Academician
MUSTAFA KORKMAZ
ÖĞRETİM GÖREVLİSİ (Unvan:Doçent) (UYGULAMALI BİRİM)
SÜLEYMAN DEMİREL ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
A quick look at recorded outputs — details below.
- Articles 45
- Projects 0
- Books 0
- Proceedings 0
- Patents 0
- Artistic 0
Scopus (SJR)
Q1
9
Q2
2
Q3
18
Q4
7
WoS (JCR)
Q1
2
Q2
5
Q3
8
Q4
18
TR Index
8
articles
Field+year+type normalized OpenAlex percentiles — not Clarivate ESI / SciVal.
Top 1% articles
0
Top 10% articles
0
Avg percentile
27.9%
Top 1% share
0.0%
Top 10% share
0.0%
Articles
Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.
Article list
- 2025 Tarlatamab in Small-Cell Lung Cancer YÖKSİS SJR Q1 JCR Q1
- 2024 The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study YÖKSİS SJR Q1 JCR Q2
- 2024 Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study YÖKSİS SJR Q1 JCR Q2
- 2024 CN33 G-8 geriatric screening tool and geriatric nutritional risk index YÖKSİS SJR Q1 JCR Q1
- 2023 The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study YÖKSİS SJR Q1 JCR Q3
- 2023 The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study YÖKSİS SJR Q1 JCR Q3
- 2022 Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group YÖKSİS SJR Q1 JCR Q2
- 2022 Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study YÖKSİS SJR Q1 JCR Q3
- 2022 The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study) YÖKSİS SJR Q1 JCR Q2